{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:03:14Z","timestamp":1772445794344,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00467-025-07043-2","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:59:19Z","timestamp":1763650759000},"page":"1087-1095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tiopronin safety in cystinuria: first real-world pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS): an EAU YAU and Endourology sections review"],"prefix":"10.1007","volume":"41","author":[{"given":"Rifat Burak","family":"Erg\u00fcl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail Taha","family":"G\u00fcrlek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F\u0131rat","family":"\u00d6zervarl\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eeyda G\u00fcl","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Pietropaolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arman","family":"Tsaturyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Julieb\u00f8-Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lazaros","family":"Tzelves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik Emre","family":"\u015eener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. \u0130rfan","family":"D\u00f6nmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayfun","family":"Oktar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Somani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-8332","authenticated-orcid":false,"given":"Tzevat","family":"Tefik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"7043_CR1","first-page":"333","volume":"45","author":"R Kachkoul","year":"2023","unstructured":"Kachkoul R, Touimi GB, El Mouhri G, El Habbani R, Mohim M, Lahrichi A (2023) Urolithiasis: history, epidemiology, aetiologic factors and management. Malays J Pathol 45:333\u2013352","journal-title":"Malays J Pathol"},{"key":"7043_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.8","volume":"2","author":"SR Khan","year":"2016","unstructured":"Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, Traxer O, Tiselius HG (2016) Kidney stones. Nat Rev Dis Primers 2:16008","journal-title":"Nat Rev Dis Primers"},{"key":"7043_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0025-6196(12)60043-3","volume":"68","author":"DS Milliner","year":"1993","unstructured":"Milliner DS, Murphy ME (1993) Urolithiasis in pediatric patients. Mayo Clin Proc 68:241\u2013248","journal-title":"Mayo Clin Proc"},{"key":"7043_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/ng0494-420","volume":"6","author":"MJ Calonge","year":"1994","unstructured":"Calonge MJ, Gasparini P, Chillar\u00f3n J, Chill\u00f3n M, Gallucci M, Rousaud F, Zelante L, Testar X, Dallapiccola B, Di Silverio F, Barcel\u00f3 P, Estivill X, Zorzano A, Nunes V, Palac\u00edn M (1994) Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet 6:420\u2013425","journal-title":"Nat Genet"},{"key":"7043_CR5","unstructured":"Skolarikos A, Jung H, Neisius A, Pet\u0159\u00edk A, Somani B, Tailly T, Gambaro G (n.d.) Uroweb-European association of urology [Internet]. EAU Guidelines on Urolithiasis-Introduction-Uroweb. Available online: https:\/\/uroweb.org\/guidelines\/urolithiasis.\u00a0Accessed 21 Dec 2023"},{"key":"7043_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ucl.2007.04.006","volume":"34","author":"A Rogers","year":"2007","unstructured":"Rogers A, Kalakish S, Desai RA, Assimos DG (2007) Management of cystinuria. Urol Clin North Am 34:347\u2013362","journal-title":"Urol Clin North Am"},{"key":"7043_CR7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2215\/CJN.10981114","volume":"10","author":"HL Rhodes","year":"2015","unstructured":"Rhodes HL, Yarram-Smith L, Rice SJ, Tabaksert A, Edwards N, Hartley A, Woodward MN, Smithson SL, Tomson C, Welsh GI, Williams M, Thwaites DT, Sayer JA, Coward RJM (2015) Clinical and genetic analysis of patients with cystinuria in the United Kingdom. Clin J Am Soc Nephrol 10:1235\u20131245","journal-title":"Clin J Am Soc Nephrol"},{"key":"7043_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00240-003-0319-0","volume":"31","author":"M Daudon","year":"2003","unstructured":"Daudon M, Cohen-Solal F, Barbey F, Gagnadoux M-F, Knebelmann B, Jungers P (2003) Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urol Res 31:207\u2013211","journal-title":"Urol Res"},{"key":"7043_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.eeus.2006.06.001","volume":"4","author":"CS Biyani","year":"2006","unstructured":"Biyani CS, Cartledge JJ (2006) Cystinuria\u2014diagnosis and management. EAU-EBU Update Series 4:175\u2013183","journal-title":"EAU-EBU Update Series"},{"key":"7043_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40620-023-01795-6","volume":"37","author":"NP Bhatt","year":"2024","unstructured":"Bhatt NP, Deshpande AV, Starkey MR (2024) Pharmacological interventions for the management of cystinuria: a systematic review. J Nephrol 37:293\u2013308","journal-title":"J Nephrol"},{"key":"#cr-split#-7043_CR11.1","unstructured":"U.S. Food and Drug Administration (2025) FDA Adverse Event Reporting System (FAERS) public dashboard [Internet]. FDA, Silver Spring"},{"key":"#cr-split#-7043_CR11.2","unstructured":"(MD) [cited 2025 Oct 29]. Available from: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard"},{"key":"7043_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Liu Y, Wu P, He X, Zhang Q (2022) Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol 13:862508","journal-title":"Front Pharmacol"},{"key":"7043_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q (2022) A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol 14:789\u2013802","journal-title":"Clin Epidemiol"},{"key":"7043_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1194545","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ran L, Liang Y, Zhang Y, An Z (2023) Safety analysis of pemigatinib leveraging the US Food and Drug Administration adverse event reporting system. Front Pharmacol 14:1194545","journal-title":"Front Pharmacol"},{"key":"7043_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.970066","volume":"13","author":"S Tang","year":"2022","unstructured":"Tang S, Wu Z, Xu L, Wen Q, Zhang X (2022) Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on FAERS. Front Pharmacol 13:970066","journal-title":"Front Pharmacol"},{"key":"7043_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B (2020) Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf 43:479\u2013487","journal-title":"Drug Saf"},{"key":"7043_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908","journal-title":"Br J Clin Pharmacol"},{"key":"7043_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7043_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7043_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1200254","volume":"14","author":"Y Wu","year":"2023","unstructured":"Wu Y, Wei M, Zhang J (2023) A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib. Front Pharmacol 14:1200254","journal-title":"Front Pharmacol"},{"key":"7043_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM (1998) A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321","journal-title":"Eur J Clin Pharmacol"},{"key":"7043_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota K, Koide D, Hirai T (2004) Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf 13:387\u2013394","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7043_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10:796\u2013803","journal-title":"Int J Med Sci"},{"key":"7043_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-018-0109-z","volume":"4","author":"Y Noguchi","year":"2018","unstructured":"Noguchi Y, Katsuno H, Ueno A, Otsubo M, Yoshida A, Kanematsu Y, Sugita I, Esaki H, Tachi T, Tsuchiya T, Teramachi H (2018) Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database. J Pharm Health Care Sci 4:15","journal-title":"J Pharm Health Care Sci"},{"key":"7043_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2023.103828","volume":"90","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Du Z, Qu K, Shen Y, Jiang Y, Zhu H, Zhang X (2023) Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database. Asian J Psychiatr 90:103828","journal-title":"Asian J Psychiatr"},{"key":"7043_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H (2024) Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disord 346:223\u2013229","journal-title":"J Affect Disord"},{"key":"7043_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf 25:381\u2013392","journal-title":"Drug Saf"},{"key":"7043_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7043_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bju.14721","volume":"124","author":"C Prot-Bertoye","year":"2019","unstructured":"Prot-Bertoye C, Lebbah S, Daudon M, Tostivint I, Jais JP, Lillo-Le Lou\u00ebt A, Pontoizeau C, Cochat P, Bataille P, Bridoux F, Brignon P, Choquenet C, Combe C, Conort P, Decramer S, Dor\u00e9 B, Dussol B, Essig M, Frimat M, Gaunez N, Joly D, Le Toquin-Bernard S, M\u00e9jean A, Meria P, Morin D, N\u2019Guyen HV, Normand M, Pietak M, Ronco P, Saussine C, Tsimaratos M, Friedlander G, Traxer O, Knebelmann B, Courbebaisse M (2019) Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France. BJU Int 124:849\u2013861","journal-title":"BJU Int"},{"key":"7043_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000188740","volume":"71","author":"A Lindell","year":"1995","unstructured":"Lindell A, Denneberg T, Jeppsson JO (1995) Urinary excretion of free cystine and the tiopronin-cysteine-mixed disulfide during long term tiopronin treatment of cystinuria. Nephron 71:328\u2013342","journal-title":"Nephron"},{"key":"7043_CR31","unstructured":"Erg\u00fcl RB SM, Aksu B, Parlakk\u0131l\u0131\u00e7 O, Y\u00fcrek Y\u0131ld\u0131r\u0131m NZ, D\u00f6nmez MI, G\u00fcven S, Y\u0131lmaz A, Oktar T, \u00d6zcan F, Ziylan O, Tefik T (2024) Treatment Compliance in Cystine Stone Patients. 41st World Congress of Endourology and Urotechnology (WCET 2024). J Endourol (Abstracts of the 41st World Congress of Endourology and Urotechnology), pp A234\u2013A235"},{"key":"7043_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1320458","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou F, Zhu C, Lou S, Cui Z, Wang D, Ou Y, Wang L, Chen J, Lan Y (2023) A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front Pharmacol 14:1320458","journal-title":"Front Pharmacol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-07043-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:12:31Z","timestamp":1772442751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-07043-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7043"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-07043-2","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"16 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any disclosures to state.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}